Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalNo recent work listed

Ke Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5929-1613; OpenAlex author ID A5100451975. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 7 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper

Papers 17

  1. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. First author DOI 10.1016/j.biopha.2022.112713↗
  2. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. First author DOI 10.1186/s13046-020-01823-4↗
  3. Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center propensity score matching study. Co-author DOI 10.1007/s13304-020-00742-5↗
  4. Total laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis with meta-analysis Co-author DOI 10.21203/rs.3.rs-20225/v1↗
  5. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  6. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  7. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  8. Laparoscopic versus open pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ijsu.2017.12.032↗
  9. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  10. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  11. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  12. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  13. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Co-author DOI 10.3892/or.2018.6281↗
  14. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  15. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  16. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  17. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 14 shared papers, 2016–2022 · strength 1.08
  2. Weikun Qian · 11 shared papers, 2017–2022 · strength 0.91
  3. Wanxing Duan · 11 shared papers, 2016–2021 · strength 0.79
  4. Jiguang Ma · 9 shared papers, 2016–2022 · strength 0.74
  5. Cancan Zhou · 10 shared papers, 2016–2021 · strength 0.73
  6. Liang Cheng · 9 shared papers, 2017–2019 · strength 0.64
  7. Liankang Sun · 9 shared papers, 2016–2019 · strength 0.63
  8. Junyu Cao · 8 shared papers, 2017–2019 · strength 0.58
  9. Zhengdong Jiang · 8 shared papers, 2016–2018 · strength 0.54
  10. Jie Li · 7 shared papers, 2017–2021 · strength 0.53
  11. Bin Yan · 7 shared papers, 2017–2019 · strength 0.49
  12. Zheng Wang · 5 shared papers, 2016–2022 · strength 0.46
  13. Jianjun Lei · 5 shared papers, 2016–2021 · strength 0.39
  14. Ying Xiao · 3 shared papers, 2019–2022 · strength 0.34
  15. Erxi Wu · 3 shared papers, 2018–2022 · strength 0.29
  16. Qinhong Xu · 4 shared papers, 2016–2019 · strength 0.27
  17. Liang Han · 3 shared papers, 2018–2021 · strength 0.26
  18. Zheng Wu · 2 shared papers, 2021–2022 · strength 0.25
  19. Tao Qin · 2 shared papers, 2021–2022 · strength 0.25
  20. Chaojie Huang · 2 shared papers, 2020 · strength 0.21
  21. Qilong Chen · 2 shared papers, 2020 · strength 0.21
  22. Xian-fa Wang · 2 shared papers, 2020 · strength 0.21
  23. Xin Chen · 3 shared papers, 2016–2018 · strength 0.18
  24. Tao Qin · 2 shared papers, 2018–2019 · strength 0.15
  25. Zheling Chen · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.